Pacira BioSciences
PCRX
260 hedge funds and large institutions have $3.01B invested in Pacira BioSciences in 2020 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 105 increasing their positions, 84 reducing their positions, and 23 closing their positions.
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
25% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 84
13% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $8.96M
3.01% more ownership
Funds ownership: 112.93% → 115.94% (+3%)
1% more funds holding
Funds holding: 257 → 260 (+3)
4% more capital invested
Capital invested by funds: $2.9B → $3.01B (+$115M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$34.2M |
| 2 |
BlackRock
New York
|
+$25.7M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$18M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$17.1M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCG
Lisanti Capital Growth
New York
|
-$10.1M |
| 2 |
Renaissance Technologies
New York
|
-$9.08M |
| 3 |
DM
Deerfield Management
New York
|
-$8.68M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.11M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$7.28M |
PCRX Hedge Fund Activity: Q4 2020 in Review
260 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2020, worth a combined $3.01B — up 4% from $2.9B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PCRX positions and 23 closed out — a net gain of 6 holders — while 105 added to existing stakes and 84 trimmed.
The largest buyer was Wells Fargo, adding an estimated $34.2M. The largest seller was Lisanti Capital Growth, exiting entirely with an estimated $10.1M sold.
- 260 institutional investors held Pacira BioSciences (PCRX) as of Q4 2020, up from 257 in Q3 2020.
- Funds reported $3.01B of Pacira BioSciences stock for Q4 2020, up 4% quarter-over-quarter.
- 29 funds opened new Pacira BioSciences positions in Q4 2020 and 23 closed out, a net change of +6 holders.
- The largest Pacira BioSciences buyer in Q4 2020 was Wells Fargo, an estimated $34.2M added.
- The largest Pacira BioSciences seller in Q4 2020 was Lisanti Capital Growth, an estimated $10.1M sold.
Based on aggregated 13F filings for Q4 2020.